---
schema_version: "secwatch.filing_event.v1"
accession: "0001689548-25-000056"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2025-05-02T23:59:59+00:00"
generated_at: "2026-05-22T22:53:49.591186+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Praxis posts Q1 net loss of $69.3M; cash $472M, runway into 2028

## Summary
- Net loss $69.3M for Q1 2025 vs $39.6M YoY; R&D spend $60.8M (up 125% YoY).
- Cash & investments $472M as of March 31, 2025; no revenue recognized.
- Essential3 essential tremor trial continues after futility interim; topline Q3 2025.
- Vormatrigine RADIANT topline mid-2025, POWER1 H2 2025; EMERALD & EMBRAVE3 studies to start mid-2025.

## SEC filing metadata
- accession: 0001689548-25-000056
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2025-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000168954825000056/0001689548-25-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000168954825000056/prax-20250502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689548-25-000056
- JSON: https://secwatch.observer/filing/0001689548-25-000056.json
- Plain text: https://secwatch.observer/filing/0001689548-25-000056.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.